Starling Oncology (STLN) director sells 298K shares under 10b5-1 plan

Rhea-AI Filing Summary

Starling Oncology, Inc. (STLN) director Brad Hively reported a sale of company stock. On August 21, 2026, he sold 298,853 shares of Starling Oncology Common Stock in a transaction coded as a sale in open market or private transaction. The reported price of $6.5126 per share is a weighted average for multiple trades executed between $6.37 and $6.75 per share. After this transaction, Hively directly holds 411,976 shares of Starling Oncology common stock. The filing affirms that the transaction was effected under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 298,853 shares

Net Sell 1 txn

Insider Hively Brad

Role Director

Sold 298,853 shs ($1.95M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	298,853	$6.5126	$1.95M

Holdings After Transaction: Common Stock — 411,976 shares (Direct)

Footnotes (1)

1. F1. Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.

Key Figures

Shares sold: 298,853 shares Weighted average sale price: $6.5126 per share Sale price range: $6.37 to $6.75 per share +2 more

5 metrics

Shares sold 298,853 shares Common Stock sold on August 21, 2026

Weighted average sale price $6.5126 per share Weighted average price for multiple sale transactions

Sale price range $6.37 to $6.75 per share Range of prices for the multiple sale transactions

Shares owned after transaction 411,976 shares Direct holdings of Brad Hively after the sale

Net shares sold 298,853 shares Net change in holdings reported in this Form 4

Key Terms

Rule 10b5-1, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 regulatory

"The filing affirms that the transaction was effected under a Rule 10b5-1 trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"Represents a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction market

"transaction code description: Sale in open market or private transaction"

FAQ

What insider transaction did STLN director Brad Hively report?

Brad Hively reported a sale of 298,853 shares of Starling Oncology, Inc. common stock on August 21, 2026, in a transaction classified as a sale in open market or private transaction.

At what price did Brad Hively sell STLN shares?

The reported price is a weighted average of $6.5126 per share. The shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share.

How many STLN shares does Brad Hively own after this sale?

After the reported sale, Brad Hively directly owns 411,976 shares of Starling Oncology, Inc. common stock, as disclosed in the filing.

Was Brad Hively’s STLN stock sale under a Rule 10b5-1 plan?

Yes. The filing indicates the Rule 10b5-1 checkbox is affirmed, meaning the reported transaction was conducted under a pre-arranged trading plan.

What is the net share change from Brad Hively’s latest STLN Form 4?

The Form 4 shows a net sale of 298,853 shares of Starling Oncology common stock, with no reported purchases or derivative exercises in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 05:11 PM Accepted by SEC EDGAR 08/24/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hively Brad

(Last) (First) (Middle)

C/O STARLING ONCOLOGY, INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Starling Oncology, Inc. [ STLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		S		298,853	D	$6.5126(1)	411,976	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)